- Home
- RPRX vs CBOE Comparison
RPRX vs CBOE Comparison
Compare RPRX & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | CBOE |
|---|---|---|
| Founded | 1996 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 25.6B |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RPRX | CBOE |
|---|---|---|
| Price | $57.16 | $252.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $51.40 | ★ $289.44 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.90% | 0.94% |
| EPS Growth | N/A | ★ 44.52 |
| EPS | 0.67 | ★ 3.66 |
| Revenue | ★ $2,378,193,000.00 | $2,229,100,000.00 |
| Revenue This Year | $38.63 | N/A |
| Revenue Next Year | $4.73 | $3.54 |
| P/E Ratio | $86.22 | ★ $68.01 |
| Revenue Growth | 5.06 | ★ 239.31 |
| 52 Week Low | $34.63 | $227.15 |
| 52 Week High | $57.79 | $371.18 |
Technical Indicators
Market Signals| Indicator | RPRX | CBOE |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 35.93 |
| Support Level | $38.07 | $241.99 |
| Resistance Level | N/A | $255.72 |
| Average True Range (ATR) | 1.50 | 12.92 |
| MACD | 0.16 | -0.32 |
| Stochastic Oscillator | 99.55 | 29.84 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.